PL-3994
 | |
| Identifiers | |
|---|---|
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C82H127N27O20S2 |
| Molar mass | 1875.21 g·mol−1 |
PL-3994 is an experimental bronchodilator that acts as an agonist of the natriuretic peptide receptor A. It is developed by Palatin Technologies.[1][2]
References
[edit]- ^ Edelson, Jeffrey D.; Makhlina, Marie; Silvester, Kevin R.; Vengurlekar, Shailesh S.; Chen, Xiaomei; Zhang, Jie; Koziol-White, Cynthia J.; Cooper, Philip R.; Hallam, Trevor J.; Hay, Douglas W.P.; Panettieri, Reynold A. (April 2013). "In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator". Pulmonary Pharmacology & Therapeutics. 26 (2): 229–238. doi:10.1016/j.pupt.2012.11.001. PMC 4070431. PMID 23154072.
- ^ Sica, Domenic; Jordan, Robert; Fischkoff, Steven A. (August 2009). "Phase IIa Study of the NPR-A Agonist, PL-3994, in Healthy Adult Volunteers with Controlled Hypertension". Journal of Cardiac Failure. 15 (6): S67. doi:10.1016/j.cardfail.2009.06.207.